Galapagos and Janssen part ways following 'therapeutic shift'

Mar 18 2015

• By Sukaina Virji

Listen to this article

Galapagos, which said in December that its partnership with Janssen Pharmaceutica was "very much alive," now says the companies have agreed to mutually terminate their inflammation alliance and option agreements. "The therapeutic indications of these programs have shifted along the way and moved outside focus areas of Janssen," Galapagos CEO Onno van de Stolpe told Scrip.

Galapagos, which said in December that its partnership with Janssen Pharmaceutica was "very much alive," now says the companies have agreed to mutually terminate their inflammation alliance and option agreements. "The therapeutic indications of these programs have shifted along the way and moved outside focus areas of Janssen," Galapagos CEO Onno van de Stolpe told Scrip.

Among others, all rights to candidate drug GLPG1690, a selective autotaxin inhibitor, have been returned to Galapagos. A first-in-human Phase...

More from Musculoskeletal

Lilly In No Hurry To Share Results From Muscle-Building And Obesity Combination
Jun 26 2024
• By Andrew McConaghie
A new muscle-building front is opening in the fight against obesity, with Lilly among the leaders. But it plans to remain tight-lipped on upcoming Phase II data for its myostatin inhibitor in combination with Novo’s Wegovy for fear of playing into the hands of its rival.
Ultragenyx Data De-Risk Phase III Trial Of Setrusumab
Jun 12 2024
• By Joseph Haas
The Mereo-partnered drug is in pivotal development for osteogenesis imperfecta. Ultragenyx also recently reported positive Phase III data for a rare disease gene therapy.
Bridgebio Ready To Challenge BioMarin In Achondroplasia
Jun 05 2024
• By Andrew McConaghie
The company sees a $5bn opportunity to treat children with achondroplasia and the less severe growth disorder variant, hypochondroplasia.
Dyne Hopes DM1 And DMD Mid-Stage Data Can Lead To Accelerated Approval
May 20 2024
• By Joseph Haas
Phase I/II data for its ADC candidates in myotonic dystrophy type 1 and Duchenne muscular dystrophy indicate potential for biomarker-based accelerated approval in both diseases, Dyne asserts.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.